New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 25, 2014
12:19 EDTCELG, ANN, SNY, ITMN, GILD, LTM, RGDO, THI, QIHU, GSK, RHHBY, BKWOn The Fly: Midday Wrap
Stocks on Wall Street continued their recent run higher, pushing the S&P 500 above 2,000 for the first time ever. The benchmark index hit the record level despite a report that showed new home sales unexpectedly declined in July. At the lunch hour, the averages were just off their best levels and the S&P had dipped back just below the 2K milestone. ECONOMIC EVENTS: In the U.S., the Chicago Fed's National Activity index jumped to 0.39 in July from an upwardly revised 0.21 in June. Markit's preliminary August services PMI came in at 58.5, which was down from a prior reading of 60.8 but above the 58.0 consensus projection. New home sales dropped 2.4% to a 412K rate in July, missing expectations for them to have risen to a 430K annualized rate. COMPANY NEWS: Shares of InterMune (ITMN) surged 35.5% to trade just below $73 per share near noon after the company agreed to be acquired by Roche (RHHBY) for $74.00 per share in an all-cash transaction. The deal announcement comes less than two weeks after Bloomberg reported that Roche, along with big pharmaceutical peers Sanofi (SNY) and GlaxoSmithKline (GSK), had made takeover bids for the smaller drugmaker. A number of other biotech companies gained following the deal announcement, including Gilead (GILD), which rose about 3%, and Celgene (CELG), which advanced 2%... Burger King (BKW) shares rose 19% after the company confirmed it is in talks regarding a potential strategic transaction with Canadian donut chain Tim Hortons (THI). The new publicly-listed company, which would be headquartered in Canada, would be the world's third-largest quick service restaurant company with about $22B in system sales and over 18,000 restaurants. Shares of Tim Horton's trading in New York also gained 20% following the confirmation of news reported by The Wall Street Journal over the weekend. MAJOR MOVERS: Among the notable gainers was Life Time Fitness (LTM), which rose 10% after confirming the company has initiated a process to explore a potential conversion of its real estate assets into a Real Estate Investment Trust, or REIT. Also higher was Ann Inc. (ANN), which gained 4.5% after Engine Capital and Red Alder, who collectively own over 1% of the company's outstanding shares, urged the company to explore value creating opportunities, including a potential sale. Among the noteworthy losers was Regado Biosciences (RGDO), which plunged 60% and was downgraded at Deutsche Bank and Jefferies after the company announced the permanent termination of enrollment in its REGULATE-PCI phase 3 trial for its lead program. Also lower after its earnings report was Chinese Internet services provider Qihoo 360 (QIHU), which dropped 8%. INDEXES: Near midday, the Dow was up 96.27, or 0.57%, to 17,097.49, the Nasdaq was up 21.29, or 0.47%, to 4,559.85, and the S&P 500 was up 11.14, or 0.56%, to 1,999.54.
News For BKW;THI;ITMN;RHHBY;RGDO;SNY;GSK;LTM;ANN;QIHU;GILD;CELG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 >>
February 2, 2016
15:10 EDTRHHBYRoche approached Pacific Biosciences about possible acquisition, Reuters says
14:32 EDTGILDNotable companies reporting after market close
Subscribe for More Information
12:33 EDTGILDGilead February weekly 83 straddle priced for 6% movement into Q4
11:52 EDTGILDGilead technical notes before earnings news
There is an active bearish head and shoulders pattern on the daily chart that became active when price broke below $93. Downside potential for the pattern, if it remains active and completes, is to the $65 to $62.50 area over time. If the news is bearish, the pattern is likely to continue to develop. If the news is a bullish surprise, it is possible that the pattern will become inactive if price can rise above $93. To void the pattern entirely would take a move above $110.
11:09 EDTSNYSanofi plans to cut 600 jobs in France over three years, Bloomberg reports
Subscribe for More Information
09:46 EDTGILDIntercept rumored to draw interest from many suitors, Daily Mail says
Subscribe for More Information
08:53 EDTCELGPiper Jaffray biopharma analyst holds an analyst/industry conference call
Subscribe for More Information
08:36 EDTRHHBYPiper Jaffray biopharma analyst holds an analyst/industry conference call
Subscribe for More Information
08:17 EDTGSKAdaptimmune, GSK expand strategic immunotherapy collaboration
Adaptimmune Therapeutics (ADAP) and GlaxoSmithKline (GSK) announced that the companies have expanded the terms of their strategic collaboration agreement to accelerate Adaptimmune's lead clinical cancer program, an affinity enhanced T-cell immunotherapy targeting NY-ESO-1, toward pivotal trials in synovial sarcoma. Adaptimmune and GSK announced a strategic collaboration and licensing agreement in June 2014 for up to five programs, including the lead NY-ESO TCR program. GSK has an option on the NY-ESO-1 program through clinical proof of concept and, on exercise, will assume full responsibility for the program.
07:42 EDTGSKPressure mounts on big pharma names to shrink, sharpen focus, FT says
Subscribe for More Information
07:24 EDTSNYSanofi, Merck mulling exiting vaccine JV, Bloomberg reports
Subscribe for More Information
06:32 EDTGSKGSK, J&J back Index Ventures' $1B biotech business spinoff, Reuters says
GlaxoSmithKline (GSK) and Johnson & Johnson (JNJ) will back a new spinoff from Index Ventures, which is spinning off its biotech portfolio into a new $1B entity, Reuters reports. The New Medicxi Ventures business will be helmed by the existing life sciences team from Index and will include all the current biotech portfolio firms, the report says. Medicxi raises $229M for a new fund in Europe with GSK and J&J each putting in 25%, Reuters reports. Reference Link
05:19 EDTSNYSanofi Pasteur launches R&D project targeting prevention of Zika virus infection
Subscribe for More Information
February 1, 2016
14:05 EDTANNMacy's announces senior executive changes amid 'evolving' consumer preferences
Subscribe for More Information
11:02 EDTRHHBYRoche: Updated cervical cancer screening guidelines support use of cobas test
Roche announced that recently updated cervical cancer screening guidelines from the American College of Obstetricians and Gynecologists support the use of its cobas HPV Test for primary cervical cancer screening as an alternative to current cytology-based cancer screening methods in women 25 and older. The College's revised Practice Bulletin 157, published in the January issue of Obstetrics & Gynecology, reinforces similar guidance issued in 2015 by the Society for Gynecologic Oncology and the American Society for Colposcopy and Cervical Pathology. The cobas HPV Test was approved by the FDA in 2011 for use in screening women 21 and older with unclear Pap test results and for co-testing with a Pap test in women 30 and older. The FDA approved it for first-line primary cervical cancer screening for women 25 and older in April 2014 following a unanimous recommendation from the independent Microbiology Devices Panel of the FDA's Medical Devices Advisory Committee. Currently utilized by more than 250 labs in the U.S., the cobas HPV Test is the only test approved in the U.S. for all three HPV testing options now supported by three major medical societies.
09:36 EDTGILDActive equity options trading on open
Active equity options trading on open: BAC AAPL FB AMZN TWTR MGM MCD NFLX GILD INTC TSLA AA BABA C
09:23 EDTGILDGilead volatility elevated into Q4 and outlook
Gilead February weekly call option implied volatility is at 62, February is at 44, March is at 38; compared to its 52-week range of 22 to 49, suggesting large near term price movement into the expected release of Q4 results on February 2.
09:05 EDTGILDGilead says EMA validates Type II variation application for Truvada
Subscribe for More Information
05:17 EDTGILDStocks with implied volatility movement; GILD PBR
Subscribe for More Information
January 31, 2016
16:13 EDTRHHBYGenentech receives orphan designation for Avastin in mesothelioma
Subscribe for More Information
1 | 2 | 3 | 4 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use